Literature DB >> 34862849

A guide to studying protein aggregation.

Joëlle A J Housmans1,2, Guiqin Wu1,2, Joost Schymkowitz1,2, Frederic Rousseau1,2.   

Abstract

Disrupted protein folding or decreased protein stability can lead to the accumulation of (partially) un- or misfolded proteins, which ultimately cause the formation of protein aggregates. Much of the interest in protein aggregation is associated with its involvement in a wide range of human diseases and the challenges it poses for large-scale biopharmaceutical manufacturing and formulation of therapeutic proteins and peptides. On the other hand, protein aggregates can also be functional, as observed in nature, which triggered its use in the development of biomaterials or therapeutics as well as for the improvement of food characteristics. Thus, unmasking the various steps involved in protein aggregation is critical to obtain a better understanding of the underlying mechanism of amyloid formation. This knowledge will allow a more tailored development of diagnostic methods and treatments for amyloid-associated diseases, as well as applications in the fields of new (bio)materials, food technology and therapeutics. However, the complex and dynamic nature of the aggregation process makes the study of protein aggregation challenging. To provide guidance on how to analyse protein aggregation, in this review we summarize the most commonly investigated aspects of protein aggregation with some popular corresponding methods.
© 2021 Federation of European Biochemical Societies.

Entities:  

Keywords:  aggregation kinetics; aggregation propensity; aggregation-prone region; amorphous aggregates; fibrils; protein aggregation; protein homeostasis; protein stability; β-sheet

Year:  2021        PMID: 34862849     DOI: 10.1111/febs.16312

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  1 in total

1.  A comparison of four technologies for detecting p53 aggregates in ovarian cancer.

Authors:  Nicole Heinzl; Katarzyna Koziel; Elisabeth Maritschnegg; Astrid Berger; Elisabeth Pechriggl; Heidi Fiegl; Alain G Zeimet; Christian Marth; Robert Zeillinger; Nicole Concin
Journal:  Front Oncol       Date:  2022-09-08       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.